Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 12, 2001, Pages 3487-3496

  Walsh, T J ^a   Goodman, J L ^a   Pappas, P ^a   Bekersky, I ^a   Buell, D N ^a   Roden, M ^a   Barrett, J ^a   Anaissie, E J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; DIPHENHYDRAMINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; FUSARIUM; HUMAN; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MUCORMYCOSIS; MYCOSIS; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; THORAX PAIN;

ADULT; AGED; ALGORITHMS; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; AREA UNDER CURVE; ASPERGILLOSIS; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MIDDLE AGED;

EID: 0035178657     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.12.3487-3496.2001     Document Type: Article

References (50)

1. AmBisome targeting to fungal infections
2. Development, characterization, efficacy, and mode of action of AmBisome, a unilamellar formulation of amphotericin
3. A high-performance liquid chromatographic assay for the determination of Amphotericin B serum concentrations after the administration of AmBisome, a liposomal Amphotericin B formulation
4. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion (ABCD) in experimental pulmonary aspergiltosis
5. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review
6. New spectrum of fungal infections in patients with cancer
7. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels
8. Renal clearance of carprofen in the isolated perfused rat kidney
9. Pharmacokinetics of hemoglobin infusion
10. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management
11. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome
12. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia
13. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: The potential role of bronchoalveolar lavage D-mannitol and galactomannan as markers of infection
14. Amphotericin B: 30 Years of clinical experience
15. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice
16. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system
17. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
18. Lipid formulations of amphotericin B: Recent progress and future directions
19. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations
20. Chest discomfort associated with liposomal amphotericin B: Report of three cases and review of the literature
21. Distribution of doubly radiolabelled amphotericin B methyl ester and amphotericin B in the non-human primate Maccaca mulatta
22. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits
23. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
24. Hypoxemia, pulmonary hypertension, and depression of cardiac output as sequelae of liposomal amphotericin B infusion
25. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce turnout necrosis factor alpha: An effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone
26. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells
27. Liposomal amphotericin B (AmBisome): Safety data from a phase II/III clinical trial
28. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: A single-center experience of 133 episodes in 116 patients
29. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: Evaluation of United Kingdom compassionate use data
30. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors
31. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes
32. Amphotericin B phospholipid interactions responsible for reduced mammalian cell toxicity
33. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths
34. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents
35. Efficacy of amphotericin B encapsulated in liposome (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients
36. Liposome-induced pulmonary hypertension: Properties and mechanism of a complement-mediated pseudoallergic reaction
37. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans
38. Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice
39. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
40. Emerging fungal pathogens: Evolving challenges to immunocompromised patients
41. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
42. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography: A novel non-invasive method for measuring responses of organism-mediated tissue injury
43. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients
44. Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits
45. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients
46. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion
47. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: Single-dose studies
48. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: Role of lipid transfer protein
49. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B
50. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia